IGF-1 LR3 1mg

97.50 USD

Availability: In stock

FREE Shipping for orders over $200 (USA Only)

$15.00 Flat Rate Shipping Worldwide (Most Countries) 

*Includes one 30mL Bacteriostatic Water with orders over $300.00

  • Buy 5 for $94.50 each and save 4%
  • Buy 10 for $91.50 each and save 7%

Buy IGF-1 LR3

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

  • IGF-1 LR3 HPLC
  • IGF-1 LR3 Mass Spectrometry
Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
  1. What Is IGF1-LR3?
  2. IGF1-LR3 Peptide Structure
  3. IGF1-LR3 Effects
  4. IGF1-LR3 Resources

What Is IGF1-LR3?

IGF1-LR3 is a modified version of insulin-like growth factor-1. The full name of the peptide is insulin-like growth factor-1 long arginine 3. All IGF-1 derivatives play prominent roles in cell division, cell proliferation, and cell-to-cell communication. Though it has similar effects, IGF-1 LR3 does not adhere to IGF binding proteins as strongly as IGF-1. This results in IGF1-LR3 remaining in the bloodstream 120 times longer than IGF-1. IGF1-LR3 gains its prolonged half-life as a result of its structural changes. The peptide is created by adding 13 amino acids to the N-terminal end of IGF-1 and by converting the glutamic acid at position 3 of IGF-1 to an arginine residue.

IGF1-LR3 Structure

3D Structure of IGF-1

3D Structure of IGF-1
Source: Protein Data Bank in Europe (PDBe)

Molecular Formula: C400H625N111O115S9
Molecular Weight: 9117.5 g/mol
PubChem CID: N/A
CAS Number: 946870-92-4

IGF1-LR3 Effects

1. Promotes Cell Division

Like IGF-1, IGF1-LR3 is a potent stimulus for cell division and proliferation. Its primary effects are on connective tissues like muscle and bone, but it also promotes cell division in liver, kidney, nerve, skin, lung, and blood tissues. IGF-1 is best thought of as a maturation hormone because it not only promotes cell proliferation, but differentiation as well. IGF-1 causes cells to mature, in other words, so that they can carry out their specialized functions.

Unlike IGF-1, IGF1-LR3 remains in the bloodstream for long periods of time. This property makes IGF1-LR3 a much more potent molecule. A dose of IGF1-LR3 provides approximately three times as much cell activation as a similar dose of IGF-1.

Note that IGF1-LR3 and all IGF-1 derivatives do not promote cell enlargement (hypertrophy), but rather promote cell division and proliferation (hyperplasia). In the case of muscle, for instance, IGF1-LR3 does not cause muscle cells to get larger, but it does increase total numbers of muscle cells.

2. Boosts Fat Metabolism and Fights Diabetes

IGF1-LR3 boosts fat metabolism in an indirect manner by binding to both the IGF-1R receptor and the insulin receptor. These actions increase glucose uptake from the blood by muscle, nerve, and liver cells. This results in an overall decrease in blood sugar levels, which then triggers adipose tissue as well as the liver to begin breaking down glycogen and triglycerides. Overall, this produces a net decrease in adipose tissue and a net energy consumption (i.e. net catabolism).

Given its role in reducing blood sugar levels, it should come as no surprise that IGF1-LR3 reduces insulin levels as well as the need for exogenous insulin in diabetes. In most cases, this translates into a 10% decrease in insulin requirements to maintain the same blood sugar levels. This fact may help scientists understand how to decrease insulin doses in individuals who have decreased insulin sensitivity and may even offer insight into preventing type 2 diabetes in the first place.

3. Impairs Myostatin

Myostatin (a.k.a. growth differentiation factor 8) is a muscle protein that primarily inhibits the growth and differentiation of muscle cells. While this function is important to prevent unregulated hypertrophy and ensure proper healing following injury, there are times when inhibiting myostatin could be of benefit. The ability to stop myostatin from functioning could be useful in conditions like Duchenne muscle dystrophy (DMD) or in people who suffer muscle loss during prolonged immobility. In these cases, inhibiting this natural enzyme could help to slow muscle breakdown, maintain strength, and stave off morbidity.

In mouse models of DMD, it has been found that IGF1-LR3 and other IGF-1 derivatives are capable of counteracting the negative effects of myostatin to protect muscle cells and prevent apoptosis. IGF1-LR3, thanks to its long half-life, is highly effective in counteracting myostatin and appears to work by activating a muscle protein called MyoD[1], [2]. MyoD is the protein normally activated by exercise (e.g. weight lifting) or tissue damage and is responsible for the muscle hypertrophy seen in body builders.

4. IGF1-LR3 In Longevity Research

IGF1-LR3 promotes tissue repair and maintenance throughout the body, making it a protective molecule against cell damage and the effects of aging. Research in cows and pigs indicates that IGF1-LR3 administration may be an effective solution for offsetting the effects of cellular aging. Ongoing research in mice seeks to determine if IGF1-LR3 might be useful in preventing progression of a wide range of conditions such as dementia, muscle atrophy, and kidney disease. This research reveals that IGF-1 administration can prolong life and reduce disability[3], [4], [5, p. 1].

Lifespan of male and female mice is correlated with IGF-1 levels.

Lifespan of male and female mice is correlated with IGF-1 levels.
Source: ResearchGate

5. IGF1-LR3 and Glucocorticoid Signaling

Glucocorticoids, secreted primarily by the adrenal glands, are important clinical drugs used to control pain and reduce inflammation in autoimmune diseases, neurological injury, cancer, and more. Unfortunately, glucocorticoids have a number of undesirable side effects such as muscle wasting, fat gain, and deterioration of bone density. There is some interest in using IGF1-LR3 to reduce the side effects of glucocorticoids and thus allow for more effective therapy[6].


  • [1] “Adipose Tissue-Derived Stem Cell Secreted IGF-1 Protects Myoblasts from the Negative Effect of Myostatin.” [Online]. Available: https://www.hindawi.com/journals/bmri/2014/129048/. [Accessed: 16-May-2019].
  • [2] N. Li, Q. Yang, R. G. Walker, T. B. Thompson, M. Du, and B. D. Rodgers, “Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis,” Endocrinology, vol. 157, no. 1, pp. 282–291, Jan. 2016.
  • [3] E. Corpas, S. M. Harman, and M. R. Blackman, “Human growth hormone and human aging,” Endocr. Rev., vol. 14, no. 1, pp. 20–39, Feb. 1993.
  • [4] W. E. Sonntag, A. Csiszar, R. deCabo, L. Ferrucci, and Z. Ungvari, “Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies,” J. Gerontol. A. Biol. Sci. Med. Sci., vol. 67, no. 6, pp. 587–598, Jun. 2012.
  • [5] “IGF-I/IGFBP system: metabolism outline and physical exercise. - PubMed - NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/22714057. [Accessed: 16-May-2019].
  • [6] B. Y. Hanaoka, C. A. Peterson, C. Horbinski, and L. J. Crofford, “Implications of glucocorticoid therapy in idiopathic inflammatory myopathies,” Nat. Rev. Rheumatol., vol. 8, no. 8, pp. 448–457, Aug. 2012.